Based on this information, it was possible to determine that SOX2‐OT increases resistance to EGFR‐TKI‐erlotinib or cisplatin treatment in A549 cells (Fig. 3C), as well as resistance to therapy in NCI‐H1975 lung cancer cells (Fig. S3C). This evidence concerns the gene EGFR and lung cancer.